Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new hope for Friedreich ataxia patients: GV101, an oral ROCK2 inhibitor from Graviton BioScience, has received FDA Fast Track designation for Friedreich ataxia (FA). The drug aims to directly boost frataxin — the protein deficient in FA — unlike the only currently approved therapy. A Phase 2 trial is set to kick off US enrollment in late 2026.
A new contender enters the Friedreich ataxia space. Graviton BioScience's GV101, an investigational oral selective ROCK2 inhibitor, has received FDA Fast Track designation for Friedreich ataxia (FA) — a rare, progressive neurodegenerative disease affecting roughly 5,000 people in the US. The designation follows FDA clearance of the company's IND application and sets the stage for a Phase 2a trial with US enrollment expected to begin in Q4 2026.
What makes GV101 different? Unlike omaveloxolone (Skyclarys) — the only FDA-approved FA therapy, which works via Nrf2 activation but doesn't directly restore frataxin — GV101 targets ROCK2 to upregulate endogenous frataxin transcription and translation. Preclinical studies showed increases in FXN mRNA and frataxin protein. The upcoming Phase 2a trial is a randomized, double-blind, placebo-controlled study testing three doses (200, 300, and 400 mg) in 16 participants per group, with an open-label extension phase.
Key Takeaways:
Why it matters: FA has just one approved treatment, and it doesn't address the root cause. GV101's frataxin-restoring mechanism could represent a meaningful step forward for patients with this debilitating disease, especially if Phase 2 data support its efficacy.
